Hess, G <br/><br/>
Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.  [electronic resource] 

 -  Bone marrow transplantation  May 2003 
 - 775-82 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Standard No.: </label>10.1038/sj.bmt.1703925  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Feasibility Studies<br/>Female<br/>Graft Survival<br/>Humans<br/>Immunity<br/>Immunosuppression Therapy<br/>Lymphoma, B-Cell--complications<br/>Lymphoma, Mantle-Cell--complications<br/>Male<br/>Middle Aged<br/>Peripheral Blood Stem Cell Transplantation--methods<br/>Prednisone--administration & dosage<br/>Radiotherapy, Adjuvant<br/>Remission Induction--methods<br/>Rituximab<br/>Survival Analysis<br/>Transplantation, Autologous<br/>Vincristine--administration & dosage